The Biosimilars Forum, in partnership with Medicines for Europe, says the U.S. can look to European policy directives to advance the biosimilars market.
The FDA issued a lengthy statement on biosimilar naming conventions—but industry groups worry it could disincentivize biosimilar development.
Industry groups are calling for clear FDA guidance on language used by biologic originators to protect market share.
The technology is improving rapidly, becoming not only more accessible but much, much cheaper.
Biosimilar drugs are poised to transform the cancer drug market—so why is uptake so slow?
As more biosimilar agents are approved by the FDA, biologic manufacturers are looking for unique ways to hold on to market share.
Biosimilar adoption is not happening as fast as once expected—will fears about future growth hold the market back?
The partial government shutdown is affecting the country in many ways—but how is it interfering with biosimilar development?
With a new ruling against the Affordable Care Act (ACA), many worry about the fate of the biosimilar market. But will it be as detrimental as feared?
2018 was meant to be a big year for the biosimilar market—but were developments as big as hoped? Find out.